Clinical Trial Update: A Study to Assess the Safety and Efficacy of 3 Doses of ALX1-11 (50, 75, and 100µg) in the Treatment of Postmenopausal Osteoporosis [Phase 2]

View source ↗

Summary

Phase 2 trial assessing safety and efficacy of three doses of ALX1-11 in postmenopausal osteoporosis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Osteoporosis

Drugs mentioned

• ALX1-11

Snippet

Sponsor: Shire | Conditions: Osteoporosis | Phase 2 | Status: COMPLETED